What tests should be included in a complete coagulation panel for evaluating unexplained bleeding, pre‑operative assessment, or anticoagulant monitoring?

Complete Coagulation Panel Components

For evaluating unexplained bleeding, pre-operative assessment, or anticoagulant monitoring, a complete coagulation panel should include PT/INR, aPTT, fibrinogen (Clauss method), and complete blood count with platelet count as universal first-line tests. 1

First-Line Testing (Universal Components)

The following tests achieved 100% consensus among international bleeding disorder specialists and should be performed in all patients 1:

• Prothrombin Time (PT)/International Normalized Ratio (INR) - Essential for warfarin monitoring, vitamin K deficiency detection, and extrinsic pathway assessment
• Activated Partial Thromboplastin Time (aPTT) - Evaluates intrinsic pathway, detects heparin effect, and screens for factor deficiencies
• Fibrinogen (Clauss method) - The gold standard for functional fibrinogen assessment 2; performed by 90% as first-line and 97% as first or second-line 1
• Complete Blood Count (CBC) with platelet count - Performed by 65% of specialists 1; essential for detecting thrombocytopenia

Additional First-Line Tests Based on Clinical Context

For unexplained bleeding evaluation, add:

• Von Willebrand Factor (VWF) testing - Performed by 84% of specialists as first-line 1; has 6.7% sensitivity for detecting clinically significant abnormalities 3
• Factor VIII, IX, and XI assays - Performed by 62% as first-line 1
• ABO blood group - Performed by 70% 1; affects VWF levels

For pre-operative assessment in healthy ASA I-II patients: No routine coagulation testing is needed unless there is suspicion of impaired hemostasis based on bleeding history 4. For all other patients (ASA III+, on anticoagulation, or positive bleeding history), perform the universal panel plus platelet function testing 4.

For anticoagulant monitoring:

• PT/INR - For warfarin
• aPTT - For unfractionated heparin
• DOAC-specific assays - Anti-factor Xa levels (calibrated for apixaban, edoxaban, rivaroxaban) or dilute thrombin time/ecarin clotting time (for dabigatran) 5

Important Caveats

What NOT to Include Routinely

Thrombin Time (TT) should NOT be part of routine panels 6. When TT and fibrinogen were separated from automatic panel orders, testing decreased by 90% without adverse effects on patient care 6. TT is only useful for:

• Detecting heparin contamination (when combined with Reptilase time) 2
• Identifying direct thrombin inhibitors 2

Tests with Limited Utility

Standard coagulation panels have poor sensitivity for bleeding disorders 3:

• PT/INR, aPTT, fibrinogen, and TT combined: only 3.7% sensitivity for detecting bleeding disorders
• These tests primarily detect vitamin K deficiency (69% of prolonged PT cases) rather than true bleeding risk 6

Avoid routine coagulation panels in these scenarios 7:

• Chest pain evaluation
• Routine pre-operative screening in healthy patients
• Prior to initiating anticoagulation
• Screening for admitted patients without specific indications

Second-Line Testing (When First-Line Normal)

If bleeding history is convincing but first-line tests are normal, proceed with 1:

• Platelet function testing (light transmission aggregometry) - 60% perform as second-line; has 26% sensitivity for bleeding disorders 3
• Additional factor assays (FII, FV, FVII, FX, FXIII) - 52-60% perform as second-line
• Factor XIII assay - Specifically important as deficiency causes delayed bleeding
• Platelet flow cytometry - 42% perform as second-line
• Fibrinolysis assays - 38% perform as second-line

Specialized Testing

Genetic testing is performed by 48% as second-line 1; consider when standard testing fails to explain significant bleeding phenotype.

Viscoelastic testing (thromboelastography/ROTEM) provides more reliable real-time coagulation assessment 7 but is typically reserved for:

• Emergency hemorrhage situations
• Massive transfusion protocols
• Cardiac surgery monitoring

Clinical Decision Algorithm

1. Start with bleeding history assessment using a validated bleeding assessment tool (used by 80% of specialists) 1
2. Exclude non-hematologic causes: hypermobility disorders (only 55% routinely exclude this) 1, scurvy, connective tissue disorders
3. Perform universal first-line panel: PT/INR, aPTT, fibrinogen (Clauss), CBC with platelets
4. Add context-specific tests: VWF and factor assays for bleeding evaluation; DOAC-specific assays for anticoagulant monitoring
5. If normal but bleeding persists: Proceed to platelet function testing and additional factor assays
6. Document as BDUC (Bleeding Disorder of Unknown Cause) if tests remain normal with convincing bleeding history - 75% of specialists formally register these patients 1